Treatment effect measures under nonproportional hazards
- 6 October 2022
- journal article
- research article
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (1) , 181-193
Abstract
In a clinical trial with a time‐to‐event endpoint the treatment effect can be measured in various ways. Under proportional hazards all reasonable measures (such as the hazard ratio and the difference in restricted mean survival time) are consistent in the following sense: Take any control group survival distribution such that the hazard rate remains above zero; if there is no benefit by any measure there is no benefit by all measures, and as the magnitude of treatment benefit increases by any measure it increases by all measures. Under nonproportional hazards, however, survival curves can cross, and the direction of the effect for any pair of measures can be inconsistent. In this paper we critically evaluate a variety of treatment effect measures in common use and identify flaws with them. In particular, we demonstrate that a treatment's benefit has two distinct and independent dimensions which can be measured by the difference in the survival rate at the end of follow‐up and the difference in restricted mean survival time, and that commonly used measures do not adequately capture both dimensions. We demonstrate that a generalized hazard difference, which can be estimated by the difference in exposure‐adjusted subject incidence rates, captures both dimensions, and that its inverse, the number of patient‐years of follow‐up that results in one fewer event (the NYNT), is an easily interpretable measure of the magnitude of clinical benefit.Keywords
This publication has 17 references indexed in Scilit:
- Benefit–Risk Assessment Using Number Needed to Treat and Number Needed to Harm for Time-to-Event EndpointsStatistics in Biopharmaceutical Research, 2016
- On the Restricted Mean Survival Time Curve in Survival AnalysisBiometrics, 2015
- Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical studyClinical Trials, 2012
- On the clinical meaningfulness of a treatment's effect on a time‐to‐event variableStatistics in Medicine, 2011
- Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomesJournal of Clinical Epidemiology, 2010
- Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trialsStatistics in Medicine, 2005
- Survival Analysis Part I: Basic concepts and first analysesBritish Journal of Cancer, 2003
- Alternatives to the hazard ratio in summarizing efficacy in time‐to‐event studies: an example from influenza trialsStatistics in Medicine, 2002
- Calculating the number needed to treat for trials where the outcome is time to an eventBMJ, 1999
- Comparative analysis of two ratesStatistics in Medicine, 1985